Currently, several ALK-i have been approved as standard treatment for ALK-rearranged NSCLC, including crizotinib (first generation), alectinib, ceritinib, brigatinib, ensartinib (second generation), and lorlatinib (third generation) (Figure 2). This evidence concerns the gene ALK and non-small cell lung carcinoma.